↑ parent cluster · ·
research dossier →

THE BELNAP FOUNDATION FOR

LAKESIDE, AZ · EIN 464457920 · Form 990PF · FY2022 · NTEE T22 · Philanthropy & Grantmaking · Micro (<$100K) · belnapfoundation.org
revenue
$335
expenses
$183
net assets
$732
employees
—
profile · synthesized from sources

The Belnap Foundation for Mitochondrial Disease was established in 2013 by a family whose children were diagnosed with Leigh syndrome, a severe form of mitochondrial disease. The foundation's mission is to raise funds for research into mitochondrial diseases and to increase awareness among the general public and healthcare professionals. They specifically support research at the Translational Genomics Research Institute (TGen).

named programs · 2 · from sources

what they call their work

Awareness and Advocacy
Participates in conferences and shares research breakthroughs to raise awareness about mitochondrial disease among the general population and healthcare professionals.
Research Funding
Supports cutting-edge research at the Translational Genomics Research Institute’s (TGen) Center for Rare Childhood Disorders in Phoenix, AZ, focusing on MTFMT-related Leigh syndrome.
activities · 2 clusters

what they do

  • Metabolic Treatment for Down Syndrome 1 activity
    • Advocacy and scientific dissemination in mitochondrial disease
      Engages in scientific advocacy by presenting research findings at major mitochondrial medicine conferences, including the Mitochondrial Medicine Society and UMDF meetings, through oral presentations and posters focused on MTFMT mutations and disease mechanisms.
  • Genomic and Translational Biomedical Research 1 activity
    • Supports research on mitochondrial disorders, including MTFMT-related Leigh Syndrome
      Supports research using genomic technologies, patient-derived iPSCs, and animal models to understand the genetic causes of mitochondrial disorders and identify potential treatments, with a focus on MTFMT-related Leigh Syndrome. Research is conducted in collaboration with institutions such as TGen’s Center for Rare Childhood Disorders and includes development of a novel mouse model for MTFMT-related Leigh Syndrome.
financials · form 990PF · fy2022

the money

revenue
Total revenue$335
Contributions & grants$335100%
Program service revenue——
Investment income$00%
Other revenue—
expenses
Total expenses$183
Program expenses—
Admin / overhead—
Fundraising—
Salaries & benefits—
Grants paid out—
balance sheet
Total assets$832
Cash—
Investments—
Liabilities—
Net assets$732
4 years on record · 2019–2022 · YoY revenue +37.3%
leadership · form 990 part vii · fy2022

who runs it

board members · 2
  • PHIL JOHNSON — DIRECTOR
  • THOMAS JEFFERSON CESSNA IV — DIRECTOR
relationships · 5

who they work with

  • ASU Partner — Supported undergraduate thesis work in 2022.
  • Mitochondrial Medicine Society Partner — Participated in their Scientific and Clinical Meeting in 2022.
  • Translational Genomics Research Institute Partner — Collaborated with Dr. Narayanan to enroll the Belnap family in a genetic study that used whole genome sequencing to identify a mutation in the MTFMT gene linked to Leigh syndrome.
  • Translational Genomics Research Institute’s (TGen) Center for Rare Childhood Disorders Partner — Supports cutting-edge research at this institute.
  • UMDF Partner — Presented at UMDF Mitochondrial Medicine 2022 and UMDF Mitochondrial Medicine Scientific and Clinical Meeting in 2019.